Close menu




April 14th, 2021 | 07:25 CEST

SAP, wallstreet:online, Bitcoin Group: Where digitization creates growth

  • Investments
Photo credits: pixabay.com

German government offices, doctors' offices and even schools show that digitization is far from complete. The current pandemic is ruthlessly exposing the problems. Processes are still too complex, characterized by media disruptions, and data cannot be exchanged efficiently. Companies that offer digital solutions and have already gained experience with digitization can be the beneficiaries of tomorrow. We present three stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE0007164600 , DE000A2GS609 , DE000A1TNV91

Table of contents:


    SAP: How are smaller customers coping with the pandemic?

    Those who think very conservatively may consider the SAP share. The Walldorf-based group has been producing software for business customers for decades and has solutions for every area that can also be interlinked. The software regulates warehousing, accounting and also human resources from a single source. In this way, SAP has been able to gain around 400,000 customers over the years. In the first 9 months of the fiscal year, SAP nevertheless reported somewhat mixed figures. Sales climbed by only 1.5%.

    To ensure that there is growth in the future, SAP is focusing on investments in research and development and wants to outsource more and more services to the cloud. By 2025, revenue from the cloud is expected to rise to over EUR 22 billion. This perspective is encouraging and also opens up price potential for the share. However, it is unclear how well the software Company's many customers will come through the crisis. As a rule, investments are postponed for the time being if the figures are not right. Since SAP's customers include more than just corporations, there are still some question marks surrounding the next quarterly figures. Otherwise, the Company remains solidly positioned - but the stock is not likely to make any great leaps.

    wallstreet:online: Media + Brokerage = Growth

    One share that has shown very dynamic development since the outbreak of the pandemic is wallstreet:online. The operator of stock market portals for discussions and financial news also entered the brokerage market more than a year ago. Smartbroker was able to exceed all growth forecasts. It quickly reached 80,000 customers and aims to win over as many as 200,000 customers with its service by the end of 2021. To make this happen, wallstreet:online recently invested in personnel. In addition to the experienced manager Matthias Hach (previously Comdirect, flatex/ViTrade and Etrade), the experienced financial expert Roland Nicklaus recently moved from the Supervisory Board to the Management Board and will be the new CFO. Nicklaus' responsibility: to intensify contact with investors.

    At the same time, wallstreet:online is working on finally offering its customers a comprehensive app. The broker has long been on a par with typical smartphone brokers in terms of conditions - with better service. If customers can soon trade even more conveniently from their smartphones, there will be hardly any arguments against the broker, which is already winning over many customers. As a further boost to growth, the wallstreet:online team is planning to link its content more effectively with the brokerage offering in the future. In concrete terms, this could mean that readers can trade directly from articles or forum posts. According to the ulterior motive, anyone who makes it easy for customers to trade should also be pleased with rising sales. The stock has recently corrected about a third of its value. Investors are likely to have in mind that the growth of a broker also costs money. But since wallstreet:online itself has the best distribution channels in its portfolio with its portals, this growth should be cheaper to realize than with the competition. The share is interesting below EUR 20.

    Bitcoin Group: Squinting at the Coinbase IPO

    Things are also exciting at Bitcoin Group. The Company has its bank, a trading center for cryptocurrencies and the know-how to develop financial products around blockchain technology. The stock ran in step with the booming cryptocurrencies for a long time but corrected after the turn of the year. In the meantime, however, the value seems to have found a bottom. The IPO of the trading platform Coinbase could also be a trendsetter for the share: If the IPO is successful and the price continues to rise, this may also justify higher valuations for Bitcoin.de, the Bitcoin Group's trading platform. The stock is attractive, but the Company is by no means without competition. Given the combination of the media business and brokerage, wallstreet:online currently looks better.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read